2024/09/02
Shanghai, September 1, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, recently announced that it has maintained its AA MSCI (Morgan Stanley Capital International) ESG rating for the fourth consecutive year. The rating reflects WuXi AppTec’s commitment to incorporating environmental and social responsibilities into the company’s business strategies and operations.
Read more2024/07/29
- Revenue Reached RMB9,259 Million in the Second Quarter, Excluding COVID-19 Commercial Projects, Up 0.3% Year-over-Year - Revenue Reached RMB17,241 Million for the First Half, Excluding COVID-19 Commercial Projects, Down 0.7% Year-over-Year - Net Profit Attributable to the Owners of the Company Reached RMB4,240 Million, and Diluted Earnings per Share (EPS) of RMB1.45 for the First Half - Adjusted Non-IFRS Net Profit Attributable to the Owners of the Company Reached RMB4,372 Million, and Adjusted Non-IFRS Diluted EPS of RMB1.50 for the First Half - Excluding COVID-19 commercial projects, Operating Cash Flow Up 48.3%/RMB1.50 billion Year-over-Year for the First Half
Read more2024/07/19
Shanghai, July 19, 2024 - WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced that it has been included in the FTSE4Good Index Series for the second consecutive year. This achievement recognizes WuXi AppTec's exceptional performance in environmental, social, and governance (ESG) practices driven by our commitment to advancing sustainability and enabling innovation for a healthier world.
Read more2024/05/23
SINGAPORE, May 23, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced the groundbreaking of its new R&D and manufacturing site in Singapore. This milestone, following the announcement of the new site in 2022, marks another step forward in WuXi AppTec’s mission to continuously enhance its CRDMO enabling platform to better support customers worldwide in advancing healthcare treatments and innovations.
Read more2024/05/23
SINGAPORE, May 23, 2024 – WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced the groundbreaking of its new R&D and manufacturing site in Singapore. This milestone, following the announcement of the new site in 2022, marks another step forward in WuXi AppTec’s mission to continuously enhance its CRDMO enabling platform to better support customers worldwide in advancing healthcare treatments and innovations.
Read more